Company Analysis
Sign in

Verrica Pharmaceuticals Inc. (VRCA)

Nasdaq: VRCA · Pharmaceutical Preparations · West Chester, PA · filing with the SEC since 2015
Full chart Alerts Compare
Grade4.4
◀ Past 4.2● Present 4.1▶ Future 5.2
4 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

10 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Verrica Pharmaceuticals Inc.’s names, not what it holds today.

Patents granted
10
7 utility, 3 design, 1976 to Dec 31, 2025
Granted in 2025
3
Against 1 in 2024 and 1 in 2023
Applications published
14
3 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'16'19'20'21'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals5
Organic fine chemistry1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
Verrica Pharmaceuticals Inc. its own name
US, as the owner printed on each patent
10 granted
12 published
Verrica Pharmaceuticals, Inc. its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
May 6, 202512,290,651Devices and methods for the treatment of body surface disordersPharmaceuticalsVerrica Pharmaceuticals Inc.
Feb 25, 202512,233,042Treatment of cutaneous disordersPharmaceuticalsVerrica Pharmaceuticals Inc.
Feb 11, 202512,221,452Synthesis of cantharidinOrganic fine chemistryVerrica Pharmaceuticals Inc.
Jul 23, 2024D1,036,656ApplicatorVerrica Pharmaceuticals Inc.
Apr 11, 2023D983,407Ampule crush toolVerrica Pharmaceuticals Inc.
Nov 9, 202111,168,091Quantification and preparation of pharmaceutical grade cantharidinPharmaceuticalsVerrica Pharmaceuticals Inc.
Oct 19, 202111,147,790Treatment of cutaneous disordersPharmaceuticalsVerrica Pharmaceuticals Inc.
Jul 6, 202111,052,064Compositions, methods and systems for the treatment of cutaneous disordersPharmaceuticalsVerrica Pharmaceuticals Inc.
Oct 27, 2020D900,312ApplicatorVerrica Pharmaceuticals Inc.
Aug 18, 202010,745,413Commercially viable synthesis of cantharidin and bioactive cantharidin derivativesPharmaceuticalsVerrica Pharmaceuticals Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 30, 20252025/0332393DEVICES AND METHODS FOR THE TREATMENT OF BODY SURFACE DISORDERSPharmaceuticalsVerrica Pharmaceuticals Inc.
Oct 2, 20252025/0302794COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERSPharmaceuticalsVerrica Pharmaceuticals Inc.
Jul 31, 20252025/0241976ADMINISTRATION OF AN ANTICANCER PEPTIDEPharmaceuticalsVerrica Pharmaceuticals Inc.
Apr 4, 20242024/0109911SYNTHESIS OF CANTHARIDINOrganic fine chemistryVerrica Pharmaceuticals Inc. · patent 12,221,452 granted from it
Dec 14, 20232023/0399217AMPULE CRUSH TOOLMedical technologyVerrica Pharmaceuticals Inc.
Dec 30, 20212021/0401793TREATMENT OF CUTANEOUS DISORDERSPharmaceuticalsVerrica Pharmaceuticals Inc. · patent 12,233,042 granted from it
Dec 16, 20212021/0386703COMPOSITIONS, METHODS AND SYSTEMS FOR THE TREATMENT OF CUTANEOUS DISORDERSPharmaceuticalsVerrica Pharmaceuticals Inc.
May 13, 20212021/0138214DEVICES AND METHODS FOR THE TREATMENT OF BODY SURFACE DISORDERSPharmaceuticalsVerrica Pharmaceuticals Inc. · patent 12,290,651 granted from it
Mar 11, 20212021/0070771COMMERCIALLY VIABLE SYNTHESIS OF CANTHARIDIN AND BIOACTIVE CANTHARIDIN DERIVATIVESPharmaceuticalsVerrica Pharmaceuticals Inc.
Aug 27, 20202020/0270269SYNTHESIS OF CANTHARIDINOrganic fine chemistryVerrica Pharmaceuticals Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 3 · Organic fine chemistry 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton VRCA · research, not advice